+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

Early Detection and Diagnosis Project Award

Cancer Research UK

Overview

This award funds exceptional science to drive transformational change in how and when early cancers and pre-cancerous states are detected and diagnosed.

Key information

Timelines

Applications for this scheme are considered twice a year. Upcoming deadline: 18 June 2026

Funding period

up to 4 years

Funding amount

up to £500k

The applicant

You can apply for this award if you’re a scientist, clinician or healthcare worker who:

is based at a UK university, medical school, hospital or research institute (including our institutes)

in most cases, is fully funded by the host institution for the duration of the award

Career stage 

We welcome researchers from all career stages to apply. In cases where an early career researcher is lead or joint lead applicant, we would strongly recommend including at least one established researcher as co-applicant for mentorship. 

We outline how we define career stages in our competency framework.  

AI Based Application Success Predictor

1. Strong scientific excellence and innovation

The strongest CRUK applications typically demonstrate:

highly novel cancer biology,
transformative therapeutic concepts,
cutting-edge technologies,
mechanistic depth,
major potential to advance oncology.

CRUK explicitly encourages “bold and creative applications.”

2. Clear translational and patient impact

CRUK reviewers strongly favor projects likely to:

improve cancer outcomes,
enable earlier diagnosis,
improve therapies,
advance precision oncology,
reduce cancer mortality,
improve survivorship and prevention.

Applications with a realistic pathway toward patient benefit are highly competitive.

3. Strong preliminary data

Competitive applications usually include:

pilot experimental findings,
translational feasibility data,
biomarker validation,
proof-of-concept therapeutic evidence,
preliminary clinical or genomic datasets.

Strong preliminary evidence substantially improves reviewer confidence.

4. Rigorous methodology and feasibility

Successful proposals generally demonstrate:

robust experimental design,
realistic recruitment and timelines,
validated assays and endpoints,
strong statistical planning,
reproducibility,
feasible milestones.

Weak feasibility or underpowered study design is a common reason for rejection.

5. Strong collaborative and multidisciplinary teams

High-scoring CRUK projects frequently involve:

oncologists,
molecular biologists,
surgeons,
bioinformaticians,
immunologists,
data scientists,
imaging specialists,
translational researchers.

Cross-institutional collaboration is particularly valued in major CRUK schemes.

6. Strong publication and academic track record

Important predictors include:

high-impact publications,
first/senior authorship,
prior grant success,
translational outputs,
international scientific recognition,
evidence of independent leadership.

Track record remains one of the strongest predictors across major CRUK schemes.

7. Alignment with CRUK strategic priorities

Applications aligned with CRUK priorities tend to perform better, especially:

early detection,
precision oncology,
immunotherapy,
cancer prevention,
AI and cancer data science,
cancers with unmet survival needs,
translational therapeutics.

8. Strong translational infrastructure

Reviewers favor applicants with access to:

clinical trial networks,
biobanks,
sequencing infrastructure,
imaging platforms,
GMP/manufacturing capability,
advanced computational support.

Institutional infrastructure strongly influences feasibility assessments.

9. Potential for long-term impact and scalability

Competitive proposals are often those likely to:

support major clinical trials,
generate practice-changing discoveries,
influence NHS cancer care,
create scalable technologies,
attract future international funding.

CRUK prioritizes research with broad and durable oncology impact.

10. Leadership and future funding potential

For fellowships and career awards, reviewers heavily assess:

independence trajectory,
leadership potential,
mentoring environment,
long-term oncology research vision,
future ability to secure major funding.

Career-development planning is particularly important for early-career investigators.

Common Reasons for Rejection

Frequent reviewer concerns include:

insufficient novelty,
weak translational significance,
poor statistical planning,
inadequate preliminary evidence,
unrealistic timelines,
weak collaboration structure,
limited feasibility,
unclear clinical impact pathway.

Specialties

Cancer

Eligibility Requirements

Our core eligibility criteria are outlined below.

We strongly encourage that you contact us for an informal and confidential discussion of your proposal prior to submitting your application. We’ll advise on your eligibility and provide guidance on submitting your application.

Sponsor Details

Sponsor Institute/Organizations: Cancer Research UK

Sponsor Type: Corporate/Non-Profit

Address: 2 Redman Place, London, E20 1JQ

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity